Eric Venker
Director, Chief Executive Officer; President & Immunovant CEO · 14 filings · Latest: Oct 1, 2026
Immunovant, Inc.
Roivant Sciences Ltd.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
IMVT | Eric Venker | Director, Chief Executive Officer | Oct 2, 2026 | Sale | $34.11 | 3,506 | $119.6K | 257,075 | |
IMVT | Eric Venker | Director, Chief Executive Officer | Oct 1, 2026 | Option Exercise | $14.46 | 92,187 | $1.3M | 346,467 | |
ROIV | Eric Venker | President & Immunovant CEO | Sep 30, 2026 | Sale | $36.62 | 200,000 | $7.3M | 1,599,154 | |
ROIV | Eric Venker | President & Immunovant CEO | Sep 30, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,799,154 | |
ROIV | Venker Eric | — | Sep 30, 2026 | Proposed Sale | $36.62 | 200,000 | $7.3M | — | |
ROIV | Eric Venker | President & Immunovant CEO | Aug 28, 2026 | Sale | $35.77 | 200,000 | $7.2M | 1,599,154 | |
ROIV | Eric Venker | President & Immunovant CEO | Aug 28, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,799,154 | |
ROIV | Venker Eric | — | Aug 28, 2026 | Proposed Sale | $35.74 | 200,000 | $7.1M | — | |
ROIV | Eric Venker | President & Immunovant CEO | Jul 27, 2026 | Sale | $34.95 | 200,000 | $7.0M | 1,613,063 | |
ROIV | Eric Venker | President & Immunovant CEO | Jul 27, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,813,063 | |
ROIV | Venker Eric | — | Jul 27, 2026 | Proposed Sale | $34.95 | 200,000 | $7.0M | — | |
IMVT | Eric Venker | Director, Chief Executive Officer | Jul 2, 2026 | Sale | $38.48 | 3,092 | $119.0K | 254,280 | |
IMVT | Eric Venker | Director, Chief Executive Officer | Jul 1, 2026 | Option Exercise | $14.46 | 92,188 | $1.3M | 344,001 | |
ROIV | Eric Venker | President & Immunovant CEO | Jun 24, 2026 | Sale | $33.16 | 200,000 | $6.6M | 1,613,063 | |
ROIV | Eric Venker | President & Immunovant CEO | Jun 24, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,813,063 | |
ROIV | Venker Eric | — | Jun 24, 2026 | Proposed Sale | $33.16 | 200,000 | $6.6M | — | |
ROIV | Eric Venker | President & Immunovant CEO | May 22, 2026 | Sale | $30.27 | 200,000 | $6.1M | 1,613,063 | |
ROIV | Eric Venker | President & Immunovant CEO | May 22, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,813,063 | |
ROIV | Venker Eric | — | May 22, 2026 | Proposed Sale | $30.27 | 200,000 | $6.1M | — | |
ROIV | Eric Venker | President & Immunovant CEO | Apr 20, 2026 | Sale | $29.59 | 200,000 | $5.9M | 1,647,546 |
Page 1 of 4
Next →